A Comprehensive Review of Metabolic Syndrome Affecting Erectile Dysfunction

Journal of Sexual Medicine

Volumn 12, Issue 4, 2015, Pages 856-875

  Kaya, Ecem ^a   Sikka, Suresh C ^b   Gur, Serap ^a,b  

^a ANKARA UNIVERSITY   (Turkey)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Erectile Dysfunction; Hypogonadism; Inflammation; Insulin Resistance; Metabolic Syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANOREXIGENIC AGENT; AROMATASE INHIBITOR; CLOMIFENE CITRATE; FARNESOID X RECEPTOR; INTERLEUKIN 6; LEPTIN; PHOSPHODIESTERASE V INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; TESTOSTERONE;

ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ADULT; AGE; ANTAGONISTS AND INHIBITORS; BODY MASS; HEALTH BEHAVIOR; LIFESTYLE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGE FACTORS; APPETITE DEPRESSANTS; AROMATASE INHIBITORS; BARIATRIC SURGERY; BODY MASS INDEX; ERECTILE DYSFUNCTION; HEALTH BEHAVIOR; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PHOSPHODIESTERASE 5 INHIBITORS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; TESTOSTERONE;

EID: 84926415690     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12828     Document Type: Review

References (223)

1. Haidara M, Mikhailidis DP, Yassin HZ, Dobutovic B, Smiljanic KT, Soskic S, Mousa SA, Rizzo M, Isenovic ER. Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. Curr Pharm Des 2011;17:3699-3712.
2. Gill H, Mugo M, Whaley-Connell A, Stump C, Sowers JR. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005;330:290-294.
3. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989;83:1168-1173.
4. Laumann EO, Waite LJ. Sexual dysfunction among older adults: Prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57-85 years of age. J Sex Med 2008;5:2300-2311.
5. Huang PL. A comprehensive definition for metabolic syndrome. Dis Models Mech 2009;2:231-237.
6. Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F, Caragnano V, Sassara M, Quistelli G, Guida P, Favale S. Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol 2011;100:515-521.
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
8. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study. J Urol 2000;163:460-463.
9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
10. O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004;39:975-984.
11. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC. Age-related changes in general and sexual health in middle-aged and older men: Results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-1380.
12. Arboix A, Alio J. Acute cardioembolic cerebral infarction: Answers to clinical questions. Curr Cardiol Rev 2012;8:54-67.
13. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. J Clin Endocrinol Metab 2009;94:1853-1878.
14. Bal K, Oder M, Sahin AS, Karataş CT, Demir O, Can E, Gümüş BH, Ozer K, Sahin O, Esen AA. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: Metabolic backgrounds of erectile dysfunction. Urology 2007;69:356-360.
15. Heidler S, Temml C, Broessner C, Mock K, Rauchenwald M, Madersbacher S, Ponholzer A. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007;177:651-654.
16. Demir T, Demir O, Kefi A, Comlekci A, Yesil S, Esen A. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol 2006;13:385-388.
17. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: Results from the Massachusetts Male Aging Study. J Urol 2006;176:222-226.
18. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
19. Norris SL, Kansagara D, Bougatsos C, Fu R, Force USPST. Screening adults for type 2 diabetes: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008;148:855-868.
20. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:10-22.
21. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
22. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: Opportunities for prevention. Diabetes Care 2003;26:645-649.
23. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002;51:3120-3127.
24. Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity and erectile dysfunction: Field overview and research priorities. J Urol 2009;182:S45-50.
25. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
26. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-1522.
27. National Center for Health Statistics (US). Health, United States, 2012: With special feature on emergency care. Hyattsville, MD: 2013. Report No.: 2013-1232.
28. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
29. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003;163:2146-2148.
30. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-1405.
31. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005;181:143-148.
32. Fillo J, Breza J, Levcikova M, Luha J, Vachulova A, Durdík Š, Labaš P. Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone? Int Urol Nephrol 2012;44:1113-1120.
33. Yao F, Liu L, Zhang Y, Huang Y, Liu D, Lin H, Liu Y, Fan R, Li C, Deng C. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol 2013;102:645-651.
34. Esposito K, Giugliano F, Martedi E, Martedì E, Feola G, Marfella R, D'Armiento M, Giugliano D. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005;28:1201-1203.
35. Billups KL, Kaiser DR, Kelly AS, Wetterling RA, Tsai MY, Hanson N, Bank AJ. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003;15:231-236.
36. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S-42S.
37. Tomada N, Tomada I, Botelho F, Cruz F, Vendeira P. Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment. J Sex Med 2011;8:831-839.
38. Arrabal-Polo MA, Arias-Santiago S, Lopez-Carmona Pintado F, Merino-Salas S, Lahoz-García C, Zuluaga-Gómez A, Arrabal-Martín M. Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction. Sci World J 2012;2012:272769-272774.
39. Pohjantahti-Maaroos H, Palomaki A. Comparison of metabolic syndrome subjects with and without erectile dysfunction-levels of circulating oxidised LDL and arterial elasticity. Int J Clin Pract 2011;65:274-280.
40. Zambon JP, Mendonca RR, Wroclawski ML, Karam A Jr, Santos RD, Carvalho JA, etal. Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: Case-control study. Sao Paulo Med J 2010;128:137-140.
41. Yao F, Liu L, Zhang Y, Huang Y, Liu D, Lin H, Liu Y, Fan R, Li C, Deng C. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol 2013;102:645-651.
42. Schipilliti M, Caretta N, Palego P, Selice R, Ferlin A, Foresta C. Metabolic syndrome and erectile dysfunction: The ultrasound evaluation of cavernosal atherosclerosis. Diabetes Care 2011;34:1875-1877.
43. Pohjantahti-Maaroos H, Palomaki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: Differences in markers of atherosclerosis. BMC Cardiovasc Disord 2011;11:36-44.
44. Pohjantahti-Maaroos H, Palomaki A. Comparison of metabolic syndrome subjects with and without erectile dysfunction-levels of circulating oxidised LDL and arterial elasticity. Int J Clin Pract 2011;65:274-280.
45. Lee YC, Liu CC, Huang CN, Li WM, Wu WJ, Yeh HC, etal. The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males. J Sex Med 2010;7:3127-3134.
46. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-2850.
47. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
48. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, Grundy SM. Harmonizing the definition of the metabolic syndrome: Comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007;99:541-548.
49. Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, Petridis DI, Kapousouzi MI, Satsoglou EA, Mikhailidis DP. The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre Study. Diabetes, Obes Metab 2005;7:397-405.
50. Muller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol 2006;16:435-443.
51. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-598.
52. Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M. Erectile dysfunction and central obesity: An Italian perspective. Asian J Androl 2014;16:581-591.
53. Ye J, Keller JN. Regulation of energy metabolism by inflammation: A feedback response in obesity and calorie restriction. Aging 2010;2:361-368.
54. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006;29:81-90.
55. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: New insights into mechanisms. Hypertension 2005;45:9-14.
56. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993;76:1140-1146.
57. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: Recent advances. Curr Opin Pharmacol 2005;5:122-128.
58. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes, Obes Metab 2007;9:813-839.
59. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11:193-199.
60. Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009;32:720-728.
61. Goncharov NP, Katsya GV, Chagina NA, Gooren LJ. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male 2008;11:118-122.
62. Wynne FL, Khalil RA. Testosterone and coronary vascular tone: Implications in coronary artery disease. J Endocrinol Invest 2003;26:181-186.
63. Shabsigh A, Kang Y, Shabsign R, Gonzalez M, Liberson G, Fisch H, Goluboff E. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med 2005;2:716-721.
64. Rochira V, Granata AR, Madeo B, Zirilli L, Rossi G, Carani C. Estrogens in males: What have we learned in the last 10 years? Asian J Androl 2005;7:3-20.
65. Srilatha B, Adaikan PG. Estrogen and phytoestrogen predispose to erectile dysfunction: Do ER-alpha and ER-beta in the cavernosum play a role? Urology 2004;63:382-386.
66. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S, Zitzmann M. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008;62:791-798.
67. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007;92:4254-4259.
68. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000;23:490-494.
69. Srilatha B, Adaikan PG. Endocrine milieu and erectile dysfunction: Is oestradiol-testosterone imbalance, a risk factor in the elderly? Asian J Androl 2011;13:569-573.
70. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006;91:3324-3328.
71. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4:1038-1045.
72. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846.
73. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-5468.
74. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006;295:1288-1299.
75. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-917.
76. Karthikeyan VJ, Blann AD, Baghdadi S, Lane DA, Gareth Beevers D, Lip GY. Endothelial dysfunction in hypertension in pregnancy: Associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clin Res Cardiol 2011;100:531-537.
77. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
78. Arrabal-Polo MA, Arias-Santiago S, Lopez-Carmona F, Merino-Salas S, Lahoz-García C, Zuluaga-Gómez A, Arrabal-Martín M. [Metabolic syndrome and hormone profile in patients with erectile dysfunction]. Actas Urol Esp 2012;36:222-227.
79. Zambon JP, Mendonca RR, Wroclawski ML, Karam Junior A, Santos RD, Carvalho JA, Wroclawski ER. Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: Case-control study. Sao Paulo Med J 2010;128:137-140.
80. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Dehò F, Montorsi F. Common grounds for erectile dysfunction and coronary artery disease. Curr Opin Urol 2004;14:361-365.
81. Jackson G, Padley S. Erectile dysfunction and silent coronary artery disease: Abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs. Int J Clin Pract 2008;62:973-976.
82. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, Roger VL, Jacobsen SJ. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009;84:108-113.
83. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, Dehò F, Rigatti P, Montorsi F, Fiorentini C. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006;27:2632-2639.
84. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011;8:272-283.
85. Longo GZ, Neves J, Luciano VM, Peres MA. Prevalence of high blood pressure levels and associated factors among adults in Southern Brazil. Arq Bras Cardiol 2009;93:387-394, 80-6.
86. Ruiz-Fernandez N, Espinoza M, Barrios E, Reigosa A. [Cardiometabolic factors in a community located at Valencia city, Venezuela]. Rev Salud Publica 2009;11:383-394.
87. Tsujimura A. The relationship between testosterone deficiency and men's health. World J Mens Health 2013;31:126-135.
88. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: Common links. Eur Urol 2007;52:1590-1600.
89. Kaur JA. Comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162-943174.
90. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007;13:RA214-221.
91. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
92. Micic D, Polovina S. [Obesity and coronary heart disease: The mechanism of atherogenic impact]. Med Pregl 2009;62(3 suppl):43-46.
93. Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The Complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review. Metabolism 2013;62:457-478.
94. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
95. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, Stefanadi E, Askitis A, Stefanadis C. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006;27:2640-2648.
96. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 2010;285:31100-31106.
97. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501.
98. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89:2697-2703.
99. Das UN. Obesity: Genes, brain, gut, and environment. Nutrition 2010;26:459-473.
100. Fiore MC, Jimenez PM, Cremonezzi D, Juncos LI, Garcia NH. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol 2011;301:F263-270.
101. Matos G, Hirotsu C, Alvarenga TA, Cintra F, Bittencourt L, Tufik S, Andersen ML. The association between TNF-alpha and erectile dysfunction complaints. Andrology 2013;1:872-878.
102. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-186.
103. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends EndocrinolMetab 2000;11:212-217.
104. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
105. Vignozzi L, Filippi S, Comeglio P, Cellai I, Sarchielli E, Morelli A, Rastrelli G, Maneschi E, Galli A, Vannelli GB, Saad F, Mannucci E, Adorini L, Maggi M. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Mol Cell Endocrinol 2014;384:143-154.
106. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
107. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, Saltin B. Searching for the exercise factor: Is IL-6 a candidate? J Muscle Res Cell Motil 2003;24:113-119.
108. Zuliani G, Volpato S, Ble A, Blè A, Bandinelli S, Corsi AM, Lauretani F, Paolisso G, Fellin R, Ferrucci L. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: The InChianti study. Atherosclerosis 2007;192:384-390.
109. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-2207.
110. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79.
111. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: Absence of development of age-related obesity. Am J Physiol Endocrinol Metab 2004;287:E182-187.
112. Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003;88:4379-4383.
113. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
114. Srilatha B, Adaikan PG, Chong YS. Relevance of oestradiol-testosterone balance in erectile dysfunction patients' prognosis. Singapore Med J 2007;48:114-118.
115. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: Association and management. Curr Urol Rep 2005;6:470-475.
116. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol/ Eur Fed Endocr Soc 2007;156:595-602.
117. Luukkaa V, Pesonen U, Huhtaniemi I, Lehtonen A, Tilvis R, Tuomilehto J, Koulu M, Huupponen R. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998;83:3243-3246.
118. Contreras C, Sanchez A, Martinez P, Raposo R, Climent B, García-Sacristán A, Benedito S, Prieto D. Insulin resistance in penile arteries from a rat model of metabolic syndrome. Br J Pharmacol 2010;161:350-364.
119. Albersen M, Lin G, Fandel TM, Zhang H, Qiu X, Lin CS, Lue TF. Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction. Urology 2011;78:e1-8.
120. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007;4:348-362. discussion 62-3.
121. Contreras C, Sanchez A, Martinez P, Raposo R, Climent B, Garcia-Sacristan A, etal. Insulin resistance in penile arteries from a rat model of metabolic syndrome. Br J Pharmacol 2010;161:350-364.
122. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007;4:348-362, discussion 62-3.
123. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992;19:I110-115.
124. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009;296:E1230-1238.
125. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-3680.
126. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996;16:368-374.
127. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Vaiss 2004;97:673-678.
128. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-109.
129. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993;70:138-143.
130. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5:149-154.
131. Sakata T, Mannami T, Baba S, Kokubo Y, Kario K, Okamoto A, Kumeda K, Ohkura N, Katayama Y, Miyata T, Tomoike H, Kato H. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): Association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004;176:355-360.
132. Caron P, Bennet A, Camare R, Louvet JP, Boneu B, Sie P. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989;38:1010-1015.
133. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J 2010;425:41-52.
134. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004;23:963-974.
135. Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, Varakis JN. Expression of adiponectin and adiponectin receptors in human pituitary gland and brain. Neuroendocrinology 2009;89:38-47.
136. Fisman EZ, Tenenbaum A. Adiponectin: A manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014;13:103-112.
137. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, etal. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-251.
138. Saad F, Gooren L, Haider A, Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 2008;40:44-48.
139. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-733.
140. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-612.
141. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010;33:776-783.
142. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2010;118:167-171.
143. Wan ZH, Wen YB, Ding QF, Xu TY. [Effects of testosterone substitution on metabolic syndrome-related factors in hypogonadal males: A meta-analysis]. Zhonghua Nan Ke Xue 2010;16:510-515.
144. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, etal. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837.
145. Miner MM, Bhattacharya RK, Blick G, Kushner H, Khera M. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med 2013;125:8-18.
146. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol/Eur Fed Endocr Soc 2006;154:899-906.
147. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, etal. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Dis 1992;16:991-997.
148. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313-3318.
149. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
150. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, etal. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: A 3-month randomized placebo-controlled trial. Diabetes Care 2001;24:2149-2151.
151. Saad F, Grahl AS, Aversa A, Yassin AA, Kadioglu A, Moncada I, Eardley I. Effects of testosterone on erectile function: Implications for the therapy of erectile dysfunction. BJU Int 2007;99:988-992.
152. Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008;40:259-264.
153. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68:203-215.
154. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST study. J Sex Med 2014;11:840-856.
155. Marin P, Holmang S, Gustafsson C, etal. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-251.
156. Ogbera OA, Sonny C, Olufemi F, Wale A. Hypogonadism and subnormal total testosterone levels in men with type 2 diabetes mellitus. J Coll Physicians Surg Pak 2011;21:517-521.
157. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011;34:557-567.
158. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, Torres LO. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004;1:69-81.
159. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-2582.
160. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, Rochira V, Sforza A, Lenzi A, Mannucci E, Maggi M. Testosterone supplementation and sexual function: A meta-analysis study. J Sex Med 2014;11:1577-1592.
161. Yassin AA, Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia 2006;38:34-37.
162. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-293.
163. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, Garolla A. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006;91:4599-4602.
164. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837.
165. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318-327.
166. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J 2009;276:5755-5767.
167. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011;34:1669-1675.
168. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: Influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004;60:500-507.
169. Tsujimura A, Takada S, Matsuoka Y, Nakayama J, Takao T, Miyagawa Y, Sonoda M, Nishizawa H, Iwahashi H, Funahashi T, Nonomura N, Okuyama A. Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: Is there a link? Int J Urol 2009;16:830-835.
170. Sola Galarza I, Lopez Lopez B, Llorente Abarca C. [Patient with testosterone deficit syndrome and dyslipidemia]. Arch Esp Urol 2013;66:752-759.
171. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-769.
172. Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006;18:400-404.
173. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612-1627.
174. Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: Evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006;27:165-175.
175. Schneider T, Gleissner J, Merfort F, Hermanns M, Beneke M, Ulbrich E. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: Results of a randomized, placebo-controlled trial. J Sex Med 2011;8:2904-2911.
176. Miner MM, Barnes A, Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: A post hoc analysis of the vardenafil statin study. J Sex Med 2010;7:1937-1947.
177. Mazo EB, Gamidov SI, Iremashvili VV, Sotnikova EM. The role of testosterone drugs in combined therapy of erectile dysfunction in patients with metabolic syndrome]. Urologiia 2007;4:63-66.
178. Suetomi T, Kawai K, Hinotsu S, Joraku A, Oikawa T, Sekido N, Miyanaga N, Shimazui T, Akaza H. Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. J Sex Med 2008;5:1443-1450.
179. Morelli A, Vignozzi L, Maggi M, Adorini L. Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta 2011;1812:859-866.
180. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011;8:57-77.
181. Bundred NJ. Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol 2009;21:60-67.
182. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes, Obes Metab 2005;7:211-215.
183. Hammoud AO, Meikle AW, Reis LO, Gibson M, Peterson CM, Carrell DT. Obesity and male infertility: A practical approach. Semin Reprod Med 2012;30:486-495.
184. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol/Eur Fed Endocr Soc 2008;158:741-747.
185. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 2006;13:129-142.
186. Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat 2012;134:1305-1313.
187. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: Who does and does not benefit? Int J Impot Res 2003;15:156-165.
188. Da Ros CT, Averbeck MA. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency-a prospective study. Int Braz J Urol 2012;38:512-518.
189. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002;26(4 suppl):S34-37.
190. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.
191. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26:262-273.
192. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 1999;281:235-242.
193. Al-Tahami BA, Ismail AA, Bee YT, Awang SA, Salha Wan Abdul Rani WR, Sanip Z, Rasool AH. The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function. Clin Hemorheol Microcirc 2013; doi: 10.3233/CH-131765.
194. Chilton M, Dunkley A, Carter P, Davies MJ, Khunti K, Gray LJ. The effect of antiobesity drugs on waist circumference: A mixed treatment comparison. Diabetes, Obes Metab 2014;16:237-247.
195. Chughtai B, Lee RK, Te AE, Kaplan SA. Metabolic syndrome and sexual dysfunction. Curr Opin Urol 2011;21:514-518.
196. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2774.
197. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
198. Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Rastrelli G, Maneschi E, Mannucci E, Maggi M. Metformin in vitro and in vivo increases adenosine signaling in rabbit corpora cavernosa. J Sex Med 2014;11:1694-1708.
199. Nugent C, Bai C, Elariny H, Gopalakrishnan P, Quigley C, Garone M Jr, Afendy M, Chan O, Wheeler A, Afendy A, Younossi ZM. Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg 2008;18:1278-1286.
200. Silvestre V, Ruano M, Garcia-Lescun MC, Aguirregoicoa E, Criado L, Rodríguez A, Marco A, García-Blanch G. [Morbid obesity, non-alcoholic fatty liver disease, metabolic syndrome and bariatric surgery]. Nutricion Hospitalaria 2007;22:602-606.
201. Brethauer SA, Aminian A, Romero-Talamas H, etal. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628-636, discussion 36-7.
202. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f5934-5949.
203. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C. [The metabolic syndrome: Effects of a pronounced weight loss induced by bariatric surgery]. Wien Klin Wochenschr 2005;117:243-254.
204. Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, Li Z, Shekelle PG. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA 2013;309:2250-2261.
205. Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A, Jenkins AL, Axelsen M. Glycemic index: Overview of implications in health and disease. Am J Clin Nutr 2002;76:266S-273.
206. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004;27:538-546.
207. Schulte DM, Hahn M, Oberhauser F, Oberhäuser F, Malchau G, Schubert M, Heppner C, Müller N, Güdelhöfer H, Faust M, Krone W, Laudes M. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms. Horm Metab Res 2014;46:283-286.
208. Esposito K, Giugliano F, Ciotola M, De Sio M, D'Armiento M, Giugliano D. Obesity and sexual dysfunction, male and female. Int J Impot Res 2008;20:358-365.
209. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes, Obes Metab 2004;6:208-215.
210. Wannamethee SG, Shaper AG, Whincup PH. Modifiable lifestyle factors and the metabolic syndrome in older men: Effects of lifestyle changes. J Am Geriatr Soc 2006;54:1909-1914.
211. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: A systematic review and meta-analysis. Eur J Endocrinol 2013;168:829-843.
212. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA 2004;291:2978-2984.
213. Landaeta-Diaz L, Fernandez JM, Da Silva-Grigoletto M, Rosado-Alvarez D, Gómez-Garduño A. Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome. Eur J Prev Cardiol 2013;20:555-564.
214. Esposito K, Ciotola M, Giugliano F, De Sio M, Giugliano G, D'Armiento M, Giugliano D. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006;18:405-410.
215. Wing RR, Rosen RC, Fava JL, Bahnson J, Brancati F, Gendrano Iii IN, Kitabchi A, Schneider SH, Wadden TA. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010;7:156-165.
216. Aljada A, Mohanty P, Ghanim H, Abdo T, Tripathy D, Chaudhuri A, Dandona P. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: Evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-690.
217. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-1454.
218. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998;31:127-131.
219. Garcia Hermoso A, Saavedra Garcia JM, Escalante Gonzalez Y, Dominguez Pachon AM. Effect of long-term physical exercise program and/or diet on metabolic syndrome in obese boys. Nutricion Hospitalaria 2014;30:94-103.
220. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, Lyons TJ. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010;29:31-40.
221. Revnic CR, Nica AS, Revnic F. The impact of physical training on endocrine modulation, muscle physiology and sexual functions in elderly men. Arch Gerontol Geriatr 2007;44(1 suppl):339-342.
222. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-3116.
223. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: Evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001;86:5755-5761.